STTT：滕皋军/翁建平/李玲发布手术治疗糖尿病临床试验结果

Core Insights - The global prevalence of Type 2 Diabetes (T2D) is rising, with 529 million cases reported in 2021, projected to exceed 1.3 billion by 2050, highlighting an increasing public health burden [2] - Current drug therapies, including GLP-1 receptor agonists, have been developed to manage high blood sugar, but a significant portion of patients still experience poor glycemic control due to clinical inertia and patient non-adherence [2] - There is an urgent need for alternative methods that can provide sustained blood sugar control independent of daily patient adherence [2] Group 1 - A multicenter, open-label, single-arm study published in the journal Signal Transduction and Targeted Therapy evaluated catheter-based endovascular denervation for T2D patients with poor glycemic control [3] - The study involved 37 patients, with 30 undergoing endovascular denervation (EDN) treatment between December 2022 and October 2023, assessing safety and efficacy [4] - The primary endpoints included the incidence of major adverse events (MAE) within 30 days post-surgery and changes in HbA1c levels at 6 months [4] Group 2 - Patients had a baseline average HbA1c of 9.0% and fasting blood glucose of 8.6 mmol/L; no MAE were observed within 30 days post-treatment [5] - At 6 months, HbA1c levels decreased by 1.0%, with significant improvements in blood glucose control observed at 1, 3, 6, and 12 months [5] - 37% of patients reported mild to moderate gastrointestinal adverse events, indicating the need for further randomized controlled trials to validate the efficacy of EDN in improving glycemic control in T2D patients [5]